Orexo AB (FRA:C5G) ROCE % : -91.34% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Orexo AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orexo AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -91.34%.

Orexo AB ROCE % Historical Data

The historical data trend for Orexo AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB ROCE % Chart

Orexo AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-2.69

-25.38

-16.98

-17.36

-31.11

Orexo AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-6.77	-6.16	-21.42	-17.98	-91.34

Orexo AB ROCE % Calculation

Orexo AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-12.197	/	( ( (70.32 - 23.529)	+	(51.71 - 20.091) )	/ 2 )
	=	-12.197	/	( (46.791	+	31.619)	/ 2 )
	=	-12.197	/	39.205
	=	-31.11 %

Orexo AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-32.652	/	( ( (61.394 - 21.519)	+	(51.71 - 20.091) )	/ 2 )
	=	-32.652	/	( ( 39.875	+	31.619 )	/ 2 )
	=	-32.652	/	35.747
	=	-91.34 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Orexo AB (FRA:C5G) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orexo AB ROCE % Related Terms

Thank you for viewing the detailed overview of Orexo AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ORXOY:USA ORX:Sweden 0H19:UK C5G:Germany

Address

Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105

Website

https://www.orexo.com

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines